Founded in 2006, F-star is a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and have improved lives. F-star is committed to working towards a future free from cancer and other serious diseases, through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments.
F-star has attracted multiple partnerships with biopharma targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS.
The novel platform of tetravalent mAb2 bispecific antibodies has a natural human antibody format. This allows for a straightforward manufacturing process and may provide a favorable safety profile and strong biological potency. Multiple clinical trials are underway.
F-star product candidates are designed to simultaneously address multiple immune-evasion pathways that limit the effectiveness of existing therapies. These are potentially first- and best-in-class drug candidates for patients with cancer who have few other options.
F-star has four second-generation immuno-oncology therapeutics in the clinic, each directed against some of the most promising immuno-oncology targets in drug development, including LAG-3 and CD137
F-star has a fantastic team of scientists, researchers, and other specialists working together to develop next-generation immunotherapies.
On 9th March 2023, following regulatory approvals, invoX announced that it has completed the acquisition of F-star Therapeutics.